🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 8 of 16

  1. Motivational Interviewing

    Cardiff Oncology

    Diabetes Mellitus

    phase 2 other terminated

    1 trial

  2. NAT01, NAT03, Placebo film coated tablets, NAT02

    Dr. Falk Pharma GmbH

    Idiopathic or Diabetic Gastroparesis

    phase 2 small molecule active

    1 trial

  3. Naltrexone hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Obesity

    phase 2 small molecule active

    1 trial

  4. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  5. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  6. ORMD 0801

    ORAMED PHARMACEUTICALS INC.

    Brittle Type I Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  7. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  8. ORMD-0801 (Insulin) capsule 8 mg BD

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  9. ORMD-0801 Capsules

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 1

    phase 2 mab completed

    1 trial

  10. ORMD-0801 Dose # 1

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  11. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  12. ORMD-0801 Treatment A

    ORAMED PHARMACEUTICALS INC.

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  13. ORMD-0801 capsules- 2x8mg

    ORAMED PHARMACEUTICALS INC.

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  14. Olatorepatide

    Regeneron UK Limited

    Overweight or Obesity

    phase 2 small molecule active

    1 trial

  15. Omnitram Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  16. Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion

    Lacuna Pharma Pty Ltd

    Diabetic Retinopathy, Retinal Vein Occlusion

    phase 2 other active

    1 trial

  17. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial

  18. Oshadi Icp

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus, Insulin-Dependent, 1

    phase 2 small molecule completed

    1 trial

  19. PEX168 or placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  20. PRAM9

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    1 trial

  21. PREGABALIN, VX-993 tablet, VX-993 Placebo, VX-993 tablet, PREGABALIN, Pregabalin placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Pain Associated With Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  22. Para-Tabs 500 mg tabletti, ODM-111 Placebo, ODM-111, ODM-111

    Orion Laboratories Pty.

    CHRONIC PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY

    phase 2 small molecule active

    1 trial

  23. Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  24. Pear

    NORTHWEST BIOTHERAPEUTICS INC

    Metabolic Syndrome

    phase 2 other completed

    1 trial

  25. Phosphate buffered saline for SC administration

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  26. Pioglitazone and azilsartan

    Takeda

    Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  27. Placebo

    IONIS PHARMACEUTICALS INC

    NAFLD

    phase 2 small molecule completed

    1 trial

  28. Placebo

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  29. Placebo (blinded)

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  30. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Type 2 diabetes and painful diabetic peripheral neuropathy

    phase 2 small molecule active

    1 trial

  31. Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111

    NovoThirteen

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  32. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  33. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  34. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  35. Placebo for AMG 133, AMG 133

    Amgen

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  36. Placebo to match LY3556050

    Eli Lilly Co.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  37. Pramlintide+Metreleptin

    Takeda

    Obesity

    phase 2 small molecule terminated

    1 trial

  38. Pro insulin peptide

    Cardiff Oncology

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  39. REGN910-3

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  40. RO7204239, RO7204239 Placebo, Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-f

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  41. Rencofilstat

    Hepion Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  42. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  43. Rybelsus 9 mg tablets, Rybelsus 1.5 mg tablets, Rybelsus 4 mg tablets, RO7795081, Rybelsus 7 mg tablets, RO7795081, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets, RO7795081, oral GLP-1R agonist (CT-996) Capsule, hard 0 mg / 1 EA - F10

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2D)

    phase 2 small molecule active

    1 trial

  44. SAB-142, SODIUM CHLORIDE

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  45. SB-509

    SANGAMO THERAPEUTICS, INC

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    4 trials

  46. SHR20004

    Jian Li

    Obesity

    phase 2 small molecule active

    1 trial

  47. SYR-619

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  48. Saxenda 6 mg/mL solution for injection in pre-filled pen, Saxenda 6 mg/mL solution for injection in pre-filled pen, Placebo for PF-07976016, Saxenda 6 mg/mL solution for injection in pre-filled pen

    Pfizer Australia Pty Ltd

    Obesity, Overweight

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.